Ashwagandha has become a staple in stress and sleep support, with emerging clinical research also highlighting its potential in areas such as women’s health. Yet as its popularity has grown, so too has scrutiny. This adaptogen’s rapid rise has been accompanied by conflicting narratives and increasing regulatory attention, creating uncertainty across an otherwise thriving category.
At the same time, consumer demand for botanicals like ashwagandha continues to accelerate, particularly among those seeking evidence-based solutions to support resilience and healthy aging. However, increased demand has also intensified questions around quality, consistency, safety, and efficacy.
Join us to bring this botanical into focus, examining the narratives that are shaping both perception and policy. Through a science-first lens, we will address emerging regulatory discourse, industry narratives and the role of standardization, clinical research and innovation in shaping a more credible future.
Grounded in transparency and science, this session offers clarity in an increasingly complex category.
*For our viewers in APAC regions, the presentation will be available on-demand immediately after the broadcast*
